Pembrolizumab for Patients with Relapsed or Refractory Extranodal NK/T-Cell Lymphoma in Korea
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose Programmed death-1 blockade with pembrolizumab has shown promising activity in relapsed/refractory (R/R) extranodal natural killer/T-cell lymphoma (NKTCL), but studies are limited, with small patient numbers.Materials and Methods Thirteen institutes involved with the Consortium for Improving Survival of Lymphoma, a Korean lymphoma study group, collected the clinical data of 59 patients treated with pembrolizumab as salvage therapy between 2016 and 2022.Results The median age of the patients was 60 years (range, 22 to 87 years), and 76.3% had advanced Ann Abor stage disease. Pembrolizumab was given to 35.6%, 40.7%, and 23.7% of the patients as second-, third-, and fourth- or higher-line chemotherapy, respectively. The overall response rate was 40.7%, with 28.8% having complete response. The estimated 2-year progression-free survival (PFS) and overall survival rates for all patients were 21.5% and 28.7%, respectively; for responders, the rates were 53.0% and 60.7%, respectively. Although not statistically significant, Eastern Cooperative Oncology Group performance status ≥ 2 (hazard ratio [HR], 1.91; 95% confidence interval [95% CI], 0.93 to 3.94; p=0.078) and stage III or IV disease (HR, 2.59; 95% CI, 0.96 to 6.96; p=0.060) were associated with a trend toward shorter PFS in multivariate analysis. Grade 3 or 4 adverse events (AEs) were noted in 12 patients (20.3%); neutropenia (10.2%), fatigue (6.8%), and pneumonitis (5.1%) were most common AEs.Conclusion In conclusion, while pembrolizumab had a modest effect on patients with R/R NKTCL, it may be a useful salvage therapy for patients with localized disease and good performance status.
Abstract
Purpose Programmed death-1 blockade with pembrolizumab has shown promising activity in relapsed/refractory (R/R) extranodal natural killer/T-cell lymphoma (NKTCL), but studies are limited, with small patient numbers.Materials and Methods Thirteen institutes involved with the Consortium for Improving Survival of Lymphoma, a Korean lymphoma study group, collected the clinical data of 59 patients treated with pembrolizumab as salvage therapy between 2016 and 2022.Results The median age of the patients was 60 years (range, 22 to 87 years), and 76.3% had advanced Ann Abor stage disease. Pembrolizumab was given to 35.6%, 40.7%, and 23.7% of the patients as second-, third-, and fourth- or higher-line chemotherapy, respectively. The overall response rate was 40.7%, with 28.8% having complete response. The estimated 2-year progression-free survival (PFS) and overall survival rates for all patients were 21.5% and 28.7%, respectively; for responders, the rates were 53.0% and 60.7%, respectively. Although not statistically significant, Eastern Cooperative Oncology Group performance status ≥ 2 (hazard ratio [HR], 1.91; 95% confidence interval [95% CI], 0.93 to 3.94; p=0.078) and stage III or IV disease (HR, 2.59; 95% CI, 0.96 to 6.96; p=0.060) were associated with a trend toward shorter PFS in multivariate analysis. Grade 3 or 4 adverse events (AEs) were noted in 12 patients (20.3%); neutropenia (10.2%), fatigue (6.8%), and pneumonitis (5.1%) were most common AEs.Conclusion In conclusion, while pembrolizumab had a modest effect on patients with R/R NKTCL, it may be a useful salvage therapy for patients with localized disease and good performance status.
참고문헌 (31)
- Jaffe ES, "Report of the Workshop on Nasal and Related Extranodal Angiocentric T", Natural Killer Cell Lymphomas. Definitions, differential diagnosis, and epidemiology, 1996, pp.20, 103~111
- Chaudhary RK, "Management of extranodal natural killer", t-cell lymphoma, nasal type, 2015, pp.15, 245~252
- Kim SJ, "Concurrent chemoradiotherapy followed by L-asparaginase-containing chemotherapy, VIDL, for localized nasal extranodal NK", T cell lymphoma : CISL08-01 phase II study, 2014, pp.93, 1895~1901
- Dong LH, "Sequential DICE combined with l-asparaginase chemotherapy followed by involved field radiation in newly diagnosed, stage IE to IIE, nasal and extranodal NK", T-cell lymphoma, 2016, pp.57, 1600~1606
- Kwong YL, "SMILE for natural killer", T-cell lymphoma : analysis of safety and efficacy from the Asia Lymphoma Study Group, 2012, pp.120, 2973~2980
- Lim SH, "Beyond first-line non-anthracycline-based chemotherapy for extranodal NK", T-cell lymphoma : clinical outcome and current perspectives on salvage therapy for patients after first relapse and progression of disease, 2017, pp.28, 2199~2205
- Huang Y, "Gene expression profiling identifies emerging oncogenic pathways operating in extranodal NK", T-cell lymphoma, nasal type, 2010, pp.115, 1226~1237
- Song TL, "Oncogenic activation of the STAT3 pathway drives PD-L1 expression in natural killer", T-cell lymphoma, 2018, pp.132, 1146~1158
- Nurieva RI, "Yin-Yang of costimulation : crucial controls of immune tolerance and function", Immunol Rev, 229, pp.88~100 (2009)
- Robert C, "A decade of immune-checkpoint inhibitors in cancer therapy", Nat Commun, 11, pp.3801~ (2020)
- Jo JC, "Expression of programmed cell death 1 and programmed cell death ligand 1 in extranodal NK", T-cell lymphoma, nasal type, 2017, pp.96, 25~31
- Kim WY, "Expression of programmed cell death ligand 1(PD-L1)in advanced stage EBV-associated extranodal NK", T cell lymphoma is associated with better prognosis, 2016, pp.469, 581~590
- Han L, "Role of programmed death ligands in effective T-cell interactions in extranodal natural killer", T-cell lymphoma, 2014, pp.8, 1461~1469
- Kwong YL, "PD1 blockade with pembrolizumab is highly effective in relapsed or refractory NK", T-cell lymphoma failing l-asparaginase, 2017, pp.129, 2437~2442
- Li X, "Activity of pembrolizumab in relapsed", refractory NK, J Hematol Oncol, pp.2018, 11[DOI]
- Kim SJ, "Comparison of efficacy of pembrolizumab between Epstein-Barr virus-positive and-negative relapsed or refractory non-Hodgkin lymphomas", Cancer Res Treat, 51, pp.611~622 (2019)
- Cheson BD, "Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma : the Lugano classification", J Clin Oncol, 32, pp.3059~3068 (2014)
- Chen BJ, "PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies", Clin Cancer Res, 19, pp.3462~3473 (2013)
- Kim SJ, "Avelumab for the treatment of relapsed or refractory extranodal NK", T-cell lymphoma : an open-label phase 2 study, 2020, pp.136, 2754~2763
- Huang H, "Sugemalimab monotherapy for patients with relapsed or refractory extranodal natural killer", T-cell lymphoma(GEMSTONE-201) : results from a single-arm, multicenter, phase II study, 2023, pp.41, 3032~3041
- Doroshow DB, "PD-L1 as a biomarker of response to immune-checkpoint inhibitors", Nat Rev Clin Oncol, 18, pp.345~362 (2021)
- Joos S, "Primary mediastinal(thymic)B-cell lymphoma is characterized by gains of chromosomal material including 9p and amplification of the REL gene", Blood, 87, pp.1571~1578 (1996)
- Lim JQ, "Whole-genome sequencing identifies responders to pembrolizumab in relapse", refractory natural-killer, Leukemia, pp.2020, 34[DOI]
- Joyce JA, "T cell exclusion, immune privilege, and the tumor microenvironment", Science, 348, pp.74~80 (2015)
- Chen DS, "Elements of cancer immunity and the cancer-immune set point", Nature, 541, pp.321~330 (2017)
- Mariathasan S, "TGFbeta attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells", Nature, 554, pp.544~548 (2018)
- Cho J, "Immune subtyping of extranodal NK", T-cell lymphoma : a new biomarker and an immune shift during disease progression, 2020, pp.33, 603~615
- Khoury T, "Tumor-infiltrating lymphocytes in breast cancer : evaluating interobserver variability, heterogeneity, and fidelity of scoring core biopsies", Am J Clin Pathol, 150, pp.441~450 (2018)
- Buisseret L, "Reliability of tumor-infiltrating lymphocyte and tertiary lymphoid structure assessment in human breast cancer", Mod Pathol, 30, pp.1204~1212 (2017)
- Park S, "Artificial intelligence-powered spatial analysis of tumor-infiltrating lymphocytes as complementary biomarker for immune checkpoint inhibition in non-small-cell lung cancer", J Clin Oncol, 40, pp.1916~1928 (2022)
- Valero C, "Pretreatment neutrophil-to-lymphocyte ratio and mutational burden as biomarkers of tumor response to immune checkpoint inhibitors", Nat Commun, 12, pp.729~ (2021)